IMRN IMMURON Ltd/S ADR

$IMRN IMMURON’s Sept. 24 SEC 20-F filing and its newly filed PROIBS distribution-contract exhibits provide the clearest evidence yet that the company is progressing from planning into near-term U.S. commercialization. The 20-F reports A$7.713 million in FY26 product sales, up 6%, including continued U.S. Travelan growth, while the newly disclosed PROIBS contract establishes minimum annual purchasing requirements and a commercial structure for the U.S. expansion. Most importantly, the SEC-filed agreement establishes November 1, 2026 as the beginning of PROIBS Year 1, indicating that the company is approaching the contractual revenue-generating phase of its U.S. expansion rather than simply discussing a future launch. The actual minimum purchase quantities and pricing are confidential/redacted, so the filings show near-term commercial progress and a new potential revenue stream, but don’t yet allow us to calculate how large that revenue contribution will be.

$IMRN All 10k of my shares are on loan now as cost to borrow remains over 500%. On Robinhood it’s 776%. I waited out the shorting game over at $LASE earlier in the year. I will do it again here for an easy multi bagger

$IMRN they will need to recoup some shares before short interest is logged at the end of the week. Borrow rate over 500% tells you how bad it is for them at this point… even though it will take a bit to publish the updated numbers, they will make all attempts to disguise how bad it got. Obvious accumulation before catalyst (partnering)

$IMRN cost to borrow is sky high over 700% - what happens when there aren’t any shares to borrow or the interest rate to borrow is too high and the company has record sales?

$IMRN anyone else seen anything similar to this before where BNY Mellon now controls 45.7% of all shares? Rare to see increasing concentrated ownership like this in a small cap?

$IMRN by now you have heard of the mysterious pneumonia death caused in a russian lab. Who do you could profit greatly from the antidote? IMM-529

$IMRN I have submitted a formal complaint to the SEC. These highly unusual and potentially harmful market activities must be thoroughly investigated, especially given the damage they can cause to shareholders.